Date: Saturday, May 30, 2020
Session Time: 3:15pm-4:00pm
Presentation Time: 3:30pm-4:00pm
*Purpose: For preventing immunological rejection after kidney transplantation, induction immunosuppressant agents such as basiliximab or rabbit anti-thymocyte globulin (r-ATG) are mostly used nowadays. We compared the graft survival, function, de novo DSA and infection status between basiliximab and low-dose r-ATG in Living donor kidney transplantation (LDKT) recipients with immunological low-risk.
*Methods: Patients received LDKT from 2003 June 11 to 2016 April 30 were included at Samsung Medical Center. Low-dose r-ATG group patients received 1.5mg/kg dose of r-ATG at op day, post-operative one and two day (total 4.5mg/kg). Basiliximab group patients received 20mg at op day and post-operative four day. Creatinine and e-GFR change, graft survival and patient survival was checked and compared. Developing of de novo DSA and infection such as CMV and BK virus were also evaluated.
*Results: Total 268 patients were included. 37 patients received r-ATG, 231 patients received basiliximab. Baseline characteristics such as age, sex, underling disease, pre-operative PRA, DSA status had no significant difference between two groups. Graft failure rate showed no significant difference (2.7% vs 4.8%, r-ATG vs basiliximab, p = 0.901), acute cellular rejection (51.4% vs 45.9%, p = 0.337) and patients mortality also (0% vs 1.3%, p = 0.989). de no DSA showed more frequent in r-ATG group (11.4% vs 2.4%, p = 0.017). Serum creatinine and e-GFR change after transplantation showed also no significant difference (p=0.159 in e-GFR, 0.537 in creatinine)Proportion of CMV antigenemia showed higher in r-ATG group than basiliximab group (73.0% vs 51.9%, p = 0.032) and BK viremia were also higher in r-ATG group (37.8% vs 15.6%, p = 0.002). However, CMV antigenemia and BK viremia did not induced risk for graft failure (p = 0.692, 0.984).
*Conclusions: LDKT patients who treated with low-dose r-ATG showed outcomes which is comparable with those of patients who treated with basilximab in terms of graft survival and function.
To cite this abstract in AMA style:Kim S, Lim M, Kwon J, Jeong E, Yang J, Kim K, Lee K, Lee O, Joh J. Comparison of Outcome Between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/comparison-of-outcome-between-low-dose-rabbit-anti-thymocyte-globulin-and-basiliximab-in-low-risk-living-donor-kidney-transplantation/. Accessed March 6, 2021.
« Back to 2020 American Transplant Congress